4D Molecular Therapeutics 

Yahoo Finance • 7 days ago

NovaBridge’s Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward

Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 ProgramThe ability to attract seasoned ophthalmolo... Full story

Yahoo Finance • 11 days ago

4DMT Appoints Kristian Humer as Chief Financial Officer

EMERYVILLE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transfo... Full story

Yahoo Finance • 13 days ago

4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transfo... Full story

Yahoo Finance • 22 days ago

4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

EMERYVILLE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transfo... Full story

Yahoo Finance • 22 days ago

4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150’s Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years

4D-150 demonstrated consistent and durable benefit across all three patient cohorts as evidenced by maintenance of visual acuity, control of retinal anatomy and reduction of treatment burden at all time points with up to 2 years of follow-... Full story

Yahoo Finance • 28 days ago

4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific

4DMT to receive $85 million upfront cash payment and expect to receive at least $50 million of cost sharing from Otsuka over the next three years for development activities supporting global registration Up to $336 million in potential reg... Full story

Yahoo Finance • last month

4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference

EMERYVILLE, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transfo... Full story

Yahoo Finance • 3 months ago

4DMT to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transfo... Full story

Yahoo Finance • 4 months ago

4D Molecular Therapeutics stock maintains Buy rating at Goldman Sachs

Investing.com - Goldman Sachs has reiterated its Buy rating and $38.00 price target on 4D Molecular Therapeutics (NASDAQ:FDMT) following the company’s second-quarter earnings report. Currently trading at $5.50, the stock sits well below... Full story

Yahoo Finance • 4 months ago

4D Molecular Therapeutics GAAP EPS of -$0.98 misses by $0.36

* 4D Molecular Therapeutics press release [https://seekingalpha.com/pr/20195847-4dmt-reports-second-quarter-2025-financial-results-operational-highlights-and-expected] (NASDAQ:FDMT [https://seekingalpha.com/symbol/FDMT]): Q2 GAAP EPS of... Full story

Yahoo Finance • 4 months ago

Unusual volume stocks in Monday's session

Unusual volume stocks are being observed in Monday's session. [unusualvolume] TOP UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT PBM [https://www.chartmill.com/stock/quote/PBM/profile] 76.28% PSYENCE BIOMEDICAL LTD (NASDAQ:P... Full story

Yahoo Finance • 4 months ago

These stocks are moving in today's after hours session

As the regular session of the US market concludes on Thursday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER... Full story

Yahoo Finance • 4 months ago

AAV for the Hereditary Retinal Diseases Market Competitive Landscape Report 2025 | Novartis, MeiraGTx, 4D Molecular Therapeutics, and Beacon Therapeutics Lead the Charge in Innovative Therapies

Company Logo Discover the competitive landscape of AAV gene therapy for hereditary retinal diseases, featuring insights on 75+ companies and 80+ drugs. This comprehensive report highlights key advancements, including collaborations, thera... Full story

Yahoo Finance • 2 years ago

4D Molecular Therapeutics Inc CEO David Kirn Sells 102,303 Shares

On January 5, 2024, David Kirn, CEO of 4D Molecular Therapeutics Inc (NASDAQ:FDMT), executed a sale of 102,303 shares of the company's stock, according to a SEC Filing. The transaction was carried out with the shares priced at $19.15 each,... Full story

Yahoo Finance • 2 years ago

4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis at 2023 NACFC

Aerosolized 4D-710 was generally well tolerated with no inflammation in any lung biopsy across Cohorts 1 and 2 (1E15 & 2E15 vg; n=7) with up to 17 months follow-upPromising, reproducible, CFTR expression significantly above normal levels a... Full story

Yahoo Finance • 2 years ago

4DMT Gains Alignment with FDA on Plan to Lift Clinical Hold on Phase 1/2 INGLAXA Clinical Trial for 4D-310 for Fabry Disease Cardiomyopathy

Initiated single non-human primate (NHP) safety study evaluating intravenous 4D-310 combined with rituximab/sirolimus (R/S) immunosuppressive regimenAmended INGLAXA protocol to minimize risk of atypical hemolytic uremic syndrome (aHUS) ass... Full story

Yahoo Finance • 2 years ago

4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 2023 NACFC

4D-710 interim data to be presented in plenary and symposium sessions at the North American Cystic Fibrosis Conference in Phoenix, Arizona held on November 2-4, 2023 Company to host webcast on Wednesday, November 1, 2023 at 4:30 p.m. ET E... Full story

Yahoo Finance • 2 years ago

4DMT Receives EMA Priority Medicines (PRIME) Designation for 4D-150 Clinical-Stage Genetic Medicine for Treatment of Wet AMD

The European Medicines Agency’s priority medicines status is granted to drug candidates that may offer a major therapeutic advantage over existing treatments or benefit patients without treatment options 4D-150 combines a novel, targeted... Full story

Yahoo Finance • 3 years ago

4DMT Announces Presentation on Aerosolized 4D-710 for Treatment of Cystic Fibrosis at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

EMERYVILLE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, today announced a presenta... Full story

Yahoo Finance • 3 years ago

4D Molecular Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights

Presented positive interim data from intravitreal 4D-150 Phase 1/2 PRISM clinical trial for wet age-related macular degeneration (wet AMD) at the 2023 ARVO Annual MeetingOn track for completion of enrollment of the Phase 2 Dose Expansion S... Full story